Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Mohr

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Scientific Reports|March 24, 2023
MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kineticsChristian Hoffmann, Christopher Mohr, Patricia Johansson, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell ViabilityPaul E Harrington, Kaustav Biswas, David Malwitz, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Identification of triazolopyridazinones as potent p38α inhibitorsBrad Herberich, Claire Jackson, Ryan P Wurz, et al.
Bioinformatics (Oxford, England)|May 1, 2019
ClinOmicsTrailbc: a visual analytics tool for breast cancer treatment stratificationLara Schneider, Tim Kehl, Kristina Thedinga, et al.
Cytotherapy|July 29, 2019
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapyFranziska Blaeschke, Milan Cedric Paul, Martin Ulrich Schuhmann, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinaseRyan P Wurz, Liping H Pettus, Bradley Henkle, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2009
Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinaseRyan P Wurz, Liping H Pettus, Shimin Xu, et al.
Hematological Oncology|July 20, 2022
Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal studyChristian Hoffmann, Philipp Rating, Nikolaos Bechrakis, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2015
Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitorsBin Wu, Hui-Ling Wang, Victor J Cee, et al.
Bioorganic & Medicinal Chemistry Letters|January 19, 2015
The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitorsHui-Ling Wang, Victor J Cee, Frank Chavez, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Scientific Reports|March 24, 2023
MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kineticsChristian Hoffmann, Christopher Mohr, Patricia Johansson, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell ViabilityPaul E Harrington, Kaustav Biswas, David Malwitz, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Identification of triazolopyridazinones as potent p38α inhibitorsBrad Herberich, Claire Jackson, Ryan P Wurz, et al.
Bioinformatics (Oxford, England)|May 1, 2019
ClinOmicsTrailbc: a visual analytics tool for breast cancer treatment stratificationLara Schneider, Tim Kehl, Kristina Thedinga, et al.
Cytotherapy|July 29, 2019
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapyFranziska Blaeschke, Milan Cedric Paul, Martin Ulrich Schuhmann, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinaseRyan P Wurz, Liping H Pettus, Bradley Henkle, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2009
Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinaseRyan P Wurz, Liping H Pettus, Shimin Xu, et al.
Hematological Oncology|July 20, 2022
Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal studyChristian Hoffmann, Philipp Rating, Nikolaos Bechrakis, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2015
Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitorsBin Wu, Hui-Ling Wang, Victor J Cee, et al.
Bioorganic & Medicinal Chemistry Letters|January 19, 2015
The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitorsHui-Ling Wang, Victor J Cee, Frank Chavez, et al.
Pageof 6